(NASDAQ: IPSC) Century Therapeutics's forecast annual revenue growth rate of -17.67% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 64.61%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.18%.
Century Therapeutics's revenue in 2025 is $6,589,000.On average, 5 Wall Street analysts forecast IPSC's revenue for 2025 to be $5,117,614,383, with the lowest IPSC revenue forecast at $34,418,013, and the highest IPSC revenue forecast at $9,396,117,604. On average, 1 Wall Street analysts forecast IPSC's revenue for 2026 to be $2,031,523,229, with the lowest IPSC revenue forecast at $2,031,523,229, and the highest IPSC revenue forecast at $2,031,523,229.
In 2027, IPSC is forecast to generate $642,756,397 in revenue, with the lowest revenue forecast at $642,756,397 and the highest revenue forecast at $642,756,397.